Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Account Payables (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed Change in Account Payables for 9 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 40.3% to -$1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$384000.0 through Dec 2025, down 116.59% year-over-year, with the annual reading at $287000.0 for FY2025, 113.82% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$1.1 million at Aytu Biopharma, down from $1.7 million in the prior quarter.
  • The five-year high for Change in Account Payables was $6.6 million in Q4 2021, with the low at -$9.9 million in Q3 2021.
  • Average Change in Account Payables over 5 years is -$186789.5, with a median of $398000.0 recorded in 2025.
  • The sharpest move saw Change in Account Payables skyrocketed 375.51% in 2021, then crashed 1174.63% in 2025.
  • Over 5 years, Change in Account Payables stood at $6.6 million in 2021, then tumbled by 167.24% to -$4.4 million in 2022, then rose by 9.42% to -$4.0 million in 2023, then surged by 54.74% to -$1.8 million in 2024, then skyrocketed by 40.3% to -$1.1 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$1.1 million, $1.7 million, and -$1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.